Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 6 of 6 descriptions
No. | 薬物名(臨床試験情報から抽出) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Anti-von Willebrand Factor Nanobody, Caplacizumab | 2件: Caplacizumab Caplacizumab,Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| 1件: VWF VWF 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| ||||||||||||||
2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | 2件: Caplacizumab Caplacizumab,Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| 1件: VWF VWF 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| ||||||||||||||
3 | CAPLACIZUMAB | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬3. CAPLACIZUMAB
| 1件: VWF VWF 💬3. CAPLACIZUMAB
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬3. CAPLACIZUMAB
| ||||||||||||||
4 | Caplacizumab (ALX-0081) | 1件: Caplacizumab Caplacizumab | 1件: Caplacizumab
Caplacizumab
💬4. Caplacizumab (ALX-0081)
| 1件: VWF VWF 💬4. Caplacizumab (ALX-0081)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬4. Caplacizumab (ALX-0081)
| ||||||||||||||
5 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | 2件: Caplacizumab Caplacizumab,Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| 1件: VWF VWF 💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬5. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| ||||||||||||||
6 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | 2件: Caplacizumab Caplacizumab,Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| 1件: VWF VWF 💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬6. Caplacizumab (an anti-von Willebrand Factor Nanobody)
|